SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VRNA, KLG, MRGM, SONN on Behalf of ShareholdersNEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Verona Pharma plc (NasdaqGM: VRNA) to Merck & Co., Inc. (
NYSE: MRK). Under the terms of the proposed transaction, shareholders of Verona will receive $107.00 in cash for each share of American Depository Share that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
VRNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verona Pharma plc Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verona Pharma plc (
NASDAQ: VRNA) to Merck for $107.00 per American Depository Share is fair to Verona shareholders.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verona Pharma plc (Nasdaq - VRNA), Olo Inc. (NYSE - OLO), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC)BALA CYNWYD, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade
Merck (
NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Verona Pharma for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion.
Small-Cap Catalyst Pharma Is Among Market's Best Price PerformersSmall-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month.
The Healthcare Companies Fighting the World’s Biggest KillersPalm Beach, FL – July 13, 2022 – FinancialNewsMedia.com News Commentary – Some of the most prevalent health conditions on the planet claim millions of lives every year. Companies from across the healthcare sector are constantly innovating to try to combat these illnesses, pushing hard to find breakthrough cures and quality of life improvements. In […]
